Telescope Innovations (TELI) Q1 2025 earnings summary

Executive summary

• Achieved $1.2 million in revenue for Q1 FY2025, driven by strong sales of DirectInject-LCT and expanded market adoption.

• Adjusted EBITA loss of $103K, reflecting strategic reinvestment to support operational growth and consistent with budget expectations.

• Advanced collaborations, notably with Pfizer on Self-Driving Labs, and expanded proprietary technology initiatives.

Financial highlights

• Revenue of $1,204,197, down from $1,504,852 in the same quarter last year.

• Expenses increased to $1,547,734 from $1,289,852 year-over-year.

• Adjusted EBITA loss of $103,177, compared to $505,171 earnings in the prior year period.

Outlook and guidance

• Management remains confident in achieving technical, strategic, and financial targets for FY2025.

• Continued reinvestment in growth and innovation expected to sustain momentum throughout the year.